This episode continues the discussion with Oliver Eden, senior business unit director at Jabil, and Travis Webb, chief scientific officer at PII, as they dive into the nuance, challenges and opportunities of autoinjectors and combination drug delivery systems.In this conversation they focus on supporting decentralized clinical studies and how connected technology can improve patient compliance, trust and cleaner data processing.This episode is presented in partnership with <a href="https://www.pharm-int.com/">⁠PII⁠</a>. Host<a href="https://www.linkedin.com/in/lorielliskatz/">⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠</a>, Head of Insights, BioSpace Guests<a href="https://www.linkedin.com/in/oliver-eden-58040412/">Oliver Eden</a>, Senior Business Unit Director, Jabil<a href="https://www.linkedin.com/in/travis-webb-a2464056/">Travis Webb</a>, Chief Scientific Officer, PII Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Cost Control to Capability Building: Rethinking Supply and Strategy in Pharma

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.